Rhelion Life Sciences’ Wholly Owned Subsidiary Filament Health Signs Letter of Intent with Darmiyan, Inc. to Explore Use of FDA De Novo Authorized BrainSee(R) AI Platform in Early Alzheimer’s Disease Trial Design
Collaboration looks to explore the use of Darmiyan's FDA De Novo authorized BrainSee® imaging platform, authorized for predicting risk of...
UREVO Announces Black Friday Sale 2026 with Its Biggest Discounts of the Year